HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Imamura, Y. Articles by Kohno, S. Search for Related Content PubMed PubMed Citation Articles by Imamura, Y. Articles by Kohno, S.

Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model

¹ Second Dept of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan. ² Dept of Anesthesia and Critical Care, University of California, San Francisco, CA, USA. ³ Both authors contributed equally to this study.

CORRESPONDENCE: K. Yanagihara, The Second Dept of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Fax: 81 958497285. E-mail: kyana-ngs{at}umin.ac.jp

Keywords: Anti-PcrV antibody, chronic airway infection, Pseudomonas aeruginosa, type III secretion system

Received: November 13, 2006
Accepted January 15, 2007

Pseudomonas aeruginosa is one of the most important pathogens in patients with chronic airway conditions, such as cystic fibrosis and diffuse panbronchiolitis. Type III secretion system-mediated virulence factors contribute to the lung damage in chronic P. aeruginosa infection.

The effects of the anti-PcrV immunoglobulin (Ig)G, which blocks the type III secretion system, were evaluated in a mouse model of chronic P. aeruginosa infection. On bacteriological examination, anti-PcrV IgG showed no bactericidal effects. On bronchoalveolar lavage fluid (BALF) analysis, total cell number and neutrophil ratios in the anti-PcrV IgG-treated groups were lower than those in the control group. In addition, macrophage inflammatory protein-2, tumour necrosis factor-, and interleukin-ß concentrations in BALF were lower in the anti-PcrV IgG-treated groups when compared with controls. Plasma anti-PcrV IgG titre was elevated after administration of anti-PcrV IgG. Although plasma titre decreased gradually, a significant concentration was maintained during the experimental period.

These data suggest that anti-PcrV immunoglobulin G reduces the inflammatory reaction caused by chronic Pseudomonas aeruginosa respiratory infection and may be useful in treating respiratory diseases.